Clinical Trials Browser

Phase 1/2 × Has results × Pluvicto × Clear all

NCT03042468 2025-09-17

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Phase 1/2 Active not recruiting

50 enrolled 19 charts

Prostatic Neoplasms

NCT03545165 2021-08-24

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

Phase 1/2 Terminated

6 enrolled 24 charts

Prostatic Neoplasms